Trade Certara, Inc. - CERT CFD

Certara, Inc. Company profile

About Certara Inc

Certara, Inc. is a provider of biosimulation software and technology-enabled services. The Company is focused on producing medicines for patients using biosimulation software and technology to transform traditional drug discovery and development. Biosimulation is a technology used to conduct virtual trials using virtual patients to better understand how drugs behave in different individuals. The Company builds its biosimulation technology on the first principles of biology, chemistry, and pharmacology with mathematical algorithms that model how medicines and diseases behave in the body. Its software and technology-enabled services include Mechanistic Biosimulation Platform (Simcyp); Empirical Pharmacokinetic and Pharmacodynamic Biosimulation (Phoenix); Scientific Informatics Platform (D360); Clinical Outcomes Databases for Biosimulation (CODEx); Authoring and Management of Regulatory Submissions Platform (GlobalSubmit), And Market Access Communication Platform (BaseCase).

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Certara Inc revenues increased 17% to $286.1M. Net loss decreased 73% to $13.3M. Revenues reflect United States segment increase of 13% to $205.4M, EMEA segment increase of 32% to $56.4M. Lower net loss reflects Stock-based Compensation in SGA decrease of 53% to $19.2M (expense), Stock-based Compensation in SGA decrease of 70% to $2.2M (expense).